WO2021163448A3 - Vaccine and methods for detecting and preventing filariasis - Google Patents

Vaccine and methods for detecting and preventing filariasis Download PDF

Info

Publication number
WO2021163448A3
WO2021163448A3 PCT/US2021/017813 US2021017813W WO2021163448A3 WO 2021163448 A3 WO2021163448 A3 WO 2021163448A3 US 2021017813 W US2021017813 W US 2021017813W WO 2021163448 A3 WO2021163448 A3 WO 2021163448A3
Authority
WO
WIPO (PCT)
Prior art keywords
detecting
filariasis
vaccine
preventing
methods
Prior art date
Application number
PCT/US2021/017813
Other languages
French (fr)
Other versions
WO2021163448A2 (en
Inventor
Ramaswamy Kalyanasundaram
Original Assignee
The Board Of Trustees Of The University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/790,277 external-priority patent/US11370814B2/en
Application filed by The Board Of Trustees Of The University Of Illinois filed Critical The Board Of Trustees Of The University Of Illinois
Priority to US17/798,189 priority Critical patent/US20230089516A1/en
Priority to AU2021218797A priority patent/AU2021218797A1/en
Priority to EP21710733.3A priority patent/EP4103225A2/en
Priority to CN202180013867.9A priority patent/CN115209916A/en
Priority to BR112022015994A priority patent/BR112022015994A2/en
Priority to CA3167346A priority patent/CA3167346A1/en
Priority to JP2022549106A priority patent/JP2023513607A/en
Publication of WO2021163448A2 publication Critical patent/WO2021163448A2/en
Publication of WO2021163448A3 publication Critical patent/WO2021163448A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.
PCT/US2021/017813 2020-02-13 2021-02-12 Vaccine and methods for detecting and preventing filariasis WO2021163448A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US17/798,189 US20230089516A1 (en) 2020-02-13 2021-02-12 Vaccine and Methods for Detecting and Preventing Filariasis
AU2021218797A AU2021218797A1 (en) 2020-02-13 2021-02-12 Vaccine and methods for detecting and preventing filariasis
EP21710733.3A EP4103225A2 (en) 2020-02-13 2021-02-12 Vaccine and methods for detecting and preventing filariasis
CN202180013867.9A CN115209916A (en) 2020-02-13 2021-02-12 Vaccines and methods for detecting and preventing filariasis
BR112022015994A BR112022015994A2 (en) 2020-02-13 2021-02-12 MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS
CA3167346A CA3167346A1 (en) 2020-02-13 2021-02-12 Vaccine and methods for detecting and preventing filariasis
JP2022549106A JP2023513607A (en) 2020-02-13 2021-02-12 Vaccines and methods for the detection and prevention of filariasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/790,277 US11370814B2 (en) 2010-11-15 2020-02-13 Vaccine and methods for detecting and preventing filariasis
US16/790,277 2020-02-13

Publications (2)

Publication Number Publication Date
WO2021163448A2 WO2021163448A2 (en) 2021-08-19
WO2021163448A3 true WO2021163448A3 (en) 2021-11-25

Family

ID=77295222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/017813 WO2021163448A2 (en) 2020-02-13 2021-02-12 Vaccine and methods for detecting and preventing filariasis

Country Status (7)

Country Link
EP (1) EP4103225A2 (en)
JP (1) JP2023513607A (en)
CN (1) CN115209916A (en)
AU (1) AU2021218797A1 (en)
BR (1) BR112022015994A2 (en)
CA (1) CA3167346A1 (en)
WO (1) WO2021163448A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015593A1 (en) * 1993-01-12 1994-07-21 Paravax, Inc. Novel parasitic helminth proteins
WO1998052971A1 (en) * 1997-05-23 1998-11-26 Heska Corporation DIROFILARIA AND $I(BRUGIA) THIOREDOXIN PEROXIDASE TYPE-2 (TPx-2) PROTEINS, NUCLEIC ACID MOLECULES, AND USES THEREOF
CN110051832A (en) * 2019-05-31 2019-07-26 四川农业大学 A kind of heart worm disease vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5207987A (en) 1990-05-21 1993-05-04 Pb Diagnostic Systems Inc. Temperature controlled chamber for diagnostic analyzer
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
WO1994001781A1 (en) 1992-07-01 1994-01-20 Behring Diagnostics, Inc. Automated analytical instrument having a fluid sample holding tray transport assembly
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6426050B1 (en) 1997-05-16 2002-07-30 Aurora Biosciences Corporation Multi-well platforms, caddies, lids and combinations thereof
US6229603B1 (en) 1997-06-02 2001-05-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for spectroscopic measurements
US6063338A (en) 1997-06-02 2000-05-16 Aurora Biosciences Corporation Low background multi-well plates and platforms for spectroscopic measurements
US5910287A (en) 1997-06-03 1999-06-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for fluorescence measurements of biological and biochemical samples
US6814933B2 (en) 2000-09-19 2004-11-09 Aurora Biosciences Corporation Multiwell scanner and scanning method
US6448089B1 (en) 1999-10-12 2002-09-10 Aurora Biosciences Corporation Multiwell scanner and scanning method
US7459314B2 (en) 2003-02-13 2008-12-02 Inverness Medical Switzerland Gmbh Lateral flow immunoassay controls
US8003407B2 (en) 2004-07-29 2011-08-23 Relia Diagnostic Systems, Llc Lateral flow system and assay
US20060051348A1 (en) 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
US7387890B2 (en) 2004-12-16 2008-06-17 Chembio Diagnostic Systems, Inc. Immunoassay devices and use thereof
US7939342B2 (en) 2005-03-30 2011-05-10 Kimberly-Clark Worldwide, Inc. Diagnostic test kits employing an internal calibration system
US7976795B2 (en) 2006-01-19 2011-07-12 Rheonix, Inc. Microfluidic systems
US20100129935A1 (en) 2008-11-25 2010-05-27 Sarah Daniel Maddison Pregnancy testing method
US20100196200A1 (en) 2009-02-05 2010-08-05 Jin Po Lee Biological test strip

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015593A1 (en) * 1993-01-12 1994-07-21 Paravax, Inc. Novel parasitic helminth proteins
WO1998052971A1 (en) * 1997-05-23 1998-11-26 Heska Corporation DIROFILARIA AND $I(BRUGIA) THIOREDOXIN PEROXIDASE TYPE-2 (TPx-2) PROTEINS, NUCLEIC ACID MOLECULES, AND USES THEREOF
CN110051832A (en) * 2019-05-31 2019-07-26 四川农业大学 A kind of heart worm disease vaccine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BORTOLATTO J ET AL: "Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis", CLINICAL & EXPERIMENTAL ALLERGY, WILEY INTERSCIENCE, UK, vol. 38, no. 10, 1 October 2008 (2008-10-01), pages 1668 - 1679, XP002666339, ISSN: 0954-7894, [retrieved on 20080709], DOI: 10.1111/J.1365-2222.2008.03036.X *
C. P. MORRIS ET AL: "A Comprehensive, Model-Based Review of Vaccine and Repeat Infection Trials for Filariasis", CLINICAL MICROBIOLOGY REVIEW, vol. 26, no. 3, 1 July 2013 (2013-07-01), US, pages 381 - 421, XP055404095, ISSN: 0893-8512, DOI: 10.1128/CMR.00002-13 *
CHAUHAN NIKHIL ET AL: "Evaluating the Vaccine Potential of a Tetravalent Fusion Protein (rBmHAXT) Vaccine Antigen Against Lymphatic Filariasis in a Mouse Model", FRONTIERS IN IMMUNOLOGY, vol. 9, 2 July 2018 (2018-07-02), XP055806853, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036175/pdf/fimmu-09-01520.pdf> DOI: 10.3389/fimmu.2018.01520 *
FRANK G R ET AL: "PURIFICATION AND CHARACTERIZATION OF THREE LARVAL EXCRETORY-SECRETORY PROTEINS OF DIROFILARIA IMMITIS", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 75, 1 January 1996 (1996-01-01), pages 221 - 229, XP000618683, ISSN: 0166-6851, DOI: 10.1016/0166-6851(95)02533-2 *
KLIMOWSKI L ET AL: "Molecular cloning, expression and enzymatic activity of a thioredoxin peroxidase from Dirofilaria immitis", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 90, no. 1, 1 December 1997 (1997-12-01), pages 297 - 306, XP027284796, ISSN: 0166-6851, [retrieved on 19971201] *
SHARON MCGONIGLE ET AL: "Immunisation of mice with fractions derived from the intestines of Dirofilaria immitis", INTERNATIONAL JOURNAL OF PARASITOLOGY, vol. 31, no. 13, 1 November 2001 (2001-11-01), GB, pages 1459 - 1466, XP055311181, ISSN: 0020-7519, DOI: 10.1016/S0020-7519(01)00272-7 *
TAMASHIRO WESLEY K. ET AL: "Dirofilaria immitis: Studies on Anti-Microfilarial Immunity in Lewis Rats", THE AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 40, no. 4, 1 April 1989 (1989-04-01), US, pages 368 - 376, XP055807325, ISSN: 0002-9637, Retrieved from the Internet <URL:http://dx.doi.org/10.4269/ajtmh.1989.40.368> DOI: 10.4269/ajtmh.1989.40.368 *

Also Published As

Publication number Publication date
EP4103225A2 (en) 2022-12-21
AU2021218797A1 (en) 2022-08-25
BR112022015994A2 (en) 2022-10-11
WO2021163448A2 (en) 2021-08-19
CN115209916A (en) 2022-10-18
CA3167346A1 (en) 2021-08-19
JP2023513607A (en) 2023-03-31

Similar Documents

Publication Publication Date Title
CY1121215T1 (en) ANTI-VACCINES WITH IMPROVED CELLULAR IMMUNOGENOCITY
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
BRPI0520330B8 (en) polynosinic-polycytidyl acid-based adjuvant
ATE406912T1 (en) IMMUNIZATION AGAINST CHLAMYDIA TRACHEOMATIS
CY1113826T1 (en) Immunosuppressants for vaccines
PE20211112A1 (en) MULTIVALENT PNEUMOCOCCAL VACCINES
WO2003080114A3 (en) Imidazoquinoline adjuvants for vaccines
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
CY1116506T1 (en) ANTIBODIES AGAINST MASP-2
ATE426412T1 (en) ADJUVANT INFLUENZA VACCINE
WO2009126356A3 (en) Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
WO2006133879A3 (en) Vaccines for immunization against helicobacter
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2006107924A3 (en) Ehrlichia canis diva (differentiate infected from vaccinated animals)
WO2012067866A8 (en) Multivalent vaccine for filariasis
EA202190184A1 (en) Modified Meningococcal fHbp polypeptides
BRPI0811908A2 (en) STREPTOCOCCUS PNEUMONIAE PILUS ANTIGENS
EA201990010A1 (en) INFECTIOUS Bronchitis Virus Vaccine
WO2021163448A3 (en) Vaccine and methods for detecting and preventing filariasis
WO2008043000A3 (en) Ehrlicia canis diva (differentiate infected from vaccinated animals)
NO20024815L (en) Treatment of fungal infections with polyene or beta-glucan synthase inhibitor anti-fungal agents combined with anti HSP90 antibodies
ATE507286T1 (en) IMMUNIZATION OF FISH AGAINST VIRUS INFECTION
WO2006117538A3 (en) Assays for diagnosis of tuberculosis and uses thereof
WO2008064181A3 (en) Prime boost canine leishmania vaccine
WO2004032599A3 (en) Novel immunogenic proteins of leptospira

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21710733

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3167346

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022549106

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022015994

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2021218797

Country of ref document: AU

Date of ref document: 20210212

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021710733

Country of ref document: EP

Effective date: 20220913

ENP Entry into the national phase

Ref document number: 112022015994

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220812